Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Recruiting
This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/11/2023
Locations: Sunpharma Site no 44, Voorhees, New Jersey
Conditions: Active Psoriatic Arthritis
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: Arthritis Rheumatic And Back Disease Associates, Voorhees, New Jersey
Conditions: Arthritis, Psoriatic
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis
Recruiting
An open label phase 3 study
Gender:
All
Ages:
18 years and above
Trial Updated:
11/02/2023
Locations: Sunpharma site no 33, Voorhees, New Jersey
Conditions: Psoriatic Arthritis
Innovations in Genicular Outcomes Registry
Recruiting
The registry will capture prospective data on patients receiving pain management for chronic pain due to knee osteoarthritis (OA) or pain optimization for knee arthroplasty due to knee OA. The OA pain therapies may include cryo nerve block, radiofrequency ablation (RFA), intra-articular (IA) corticosteroids, viscosupplementation, opioids, and others (e.g., non-steroidal anti-inflammatory drugs [NSAIDs]).
Gender:
All
Ages:
All
Trial Updated:
10/19/2023
Locations: Jersey City Medical Center, Jersey City, New Jersey
Conditions: Knee Osteoarthritis
A Study of Baricitinib in Participants With Rheumatoid Arthritis
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: Arthritis Care Medical Center, Somerset, New Jersey +2 locations
Conditions: Rheumatoid Arthritis
Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Recruiting
Evaluate long-term safety and tolerability of tofacitinib in patients with JIA, who have previously participated in tofacitinib JIA studies.
Gender:
All
Ages:
Between 2 years and 18 years
Trial Updated:
09/08/2023
Locations: Hackensack University Medical Center, Hackensack, New Jersey +1 locations
Conditions: Juvenile Idiopathic Arthritis
Autologous Adipose-derived Stromal Vascular Fraction for Treatment of Knee Osteoarthritis
Recruiting
This study is a pivotal study to evaluate the efficacy and safety of a single injection of autologous adipose-derived SVF produced using the GID SVF-2 device system for treatment of pain with concomitant improvement in function associated with osteoarthritis of the knee joint.
Gender:
All
Ages:
Between 35 years and 85 years
Trial Updated:
09/07/2023
Locations: New Jersey Regenerative Institute, Cedar Knolls, New Jersey
Conditions: Osteoarthritis, Knee
Persona Revision Knee System Outcomes
Recruiting
The study will evaluate the performance, clinical benefits and safety of the Persona Revision Knee System in patients who have received primary or revision total knee arthroplasty (TKA) treatment. This will be done using a multicenter, single-arm, consecutive series, retrospective cohort study with prospective follow-up.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/27/2023
Locations: Orthopaedic Research Institute of New Jersey, Chester, New Jersey
Conditions: Arthroplasty Complications, Infection, Knee Disease, Knee Osteoarthritis
A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566
Recruiting
This is a single center randomized parallel-group partially-blinded, 4-arm Phase 1 study to evaluate the phototoxic potential of two dose levels of SAR441566 treatment compared to placebo and the active comparator, ciprofloxacin, in healthy adults, 18 to 55 years of age. There will be two parts: Part I is a randomized placebo-controlled trial comparing sensitivity to ultraviolet (UV) light in participants treated with SAR441566 to those treated with placebo. Part II is an open label arm consis... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
08/01/2023
Locations: TKL Research, Inc.-Site Number:8400001, Fair Lawn, New Jersey
Conditions: Rheumatoid Arthritis
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
Recruiting
This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.
Gender:
All
Ages:
Between 2 years and 16 years
Trial Updated:
08/01/2023
Locations: Hackensack University Medical Center, Hackensack, New Jersey +1 locations
Conditions: Juvenile Idiopathic Arthritis
Accuracy of Pediatric Emergency Medicine Providers in Diagnosing Hip Effusions Using Point of Care Ultrasound
Recruiting
The purpose of this study is to determine if pediatric emergency medicine providers can accurately diagnose a hip effusion using point-of-care ultrasound (POCUS) compared to radiology ultrasound (RADUS).
Gender:
All
Ages:
Between 1 month and 18 years
Trial Updated:
07/25/2023
Locations: Newark Beth Israel Medical Center, Newark, New Jersey
Conditions: Hip Effusion, Septic Arthritis, Transient Synovitis, Hip
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
Recruiting
This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/06/2023
Locations: Aclaris Clinical Operations, Freehold, New Jersey
Conditions: Psoriatic Arthritis